A better understanding of these mechanisms and connection to hyperexcitability in AD and DLB may allow for more targeted therapeutics beyond rapamycin in lessening the overactivation of mTOR and burden of its wide-ranging effects. The gene discussed is MTOR; the disease is Lewy body dementia.